Sleep Medicine: X最新文献

{"title":"Erratum to “Association of food intake with sleep disorders in children and adolescents with obesity” [Sleep Med: X 4 (2022) 100053]","authors":"Raquel S.M. Zarpellon , Dra Regina M. Vilela , Fernando Mazzilli Louzada , Dra Rosana B. Radominski , Dra Ana Chrystina de Souza Crippa","doi":"10.1016/j.sleepx.2024.100132","DOIUrl":"10.1016/j.sleepx.2024.100132","url":null,"abstract":"","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"8 ","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143141246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"REM sleep behavior disorder and Prodromal Parkinson’s Disease in patients with Essential Tremor","authors":"Paulo Bugalho ,&nbsp;Bruna Meira ,&nbsp;André Pinho ,&nbsp;Rita Ventura ,&nbsp;Marta Magriço ,&nbsp;Miguel Serôdio ,&nbsp;Danna Krupka ,&nbsp;Vítor Mendes Ferreira","doi":"10.1016/j.sleepx.2024.100118","DOIUrl":"https://doi.org/10.1016/j.sleepx.2024.100118","url":null,"abstract":"<div><p>Several studies suggested the presence of non-motor symptoms in Essential Tremor (ET), including REM sleep behavioral disorder (RBD). RBD is an essential criterion for Prodromal Parkinson's Disease (PPD), suggesting a link between ET and PD. Our objective was to assess the prevalence and features of ET patients with RBD and PDD.</p><p>RBD was diagnosed by questionnaire screening, followed by polysomnography. PPD risk factors and prodromic markers were assessed with a structured protocol. Patients were characterized regarding tremor features. ET patients with RBD (ET-RBD) and PPD (ET-PPD) were compared to patients without RBD (ET-nonRBD) and without PPD (ET-nonPPD), respectively. ET-RBD patients were also compared with a group of isolated RBD (iRBD) regarding PPD features.</p><p>We assessed a total of 64 ET patients. Five (8.3 %) and 4 (6.3 %) had criteria for RBD and PPD, respectively. ET-RBD patients did not differ from ET-nonRBD except for a higher prevalence of PPD. There were no significant differences between ET-RBD and iRBD (n = 12) groups. ET-PPD had a higher prevalence of positive DaT-Scans and RBD compared to ET-nonPPD. Three ET-RBD patients had PPD and 3 ET-PPD had RBD.</p><p>Both RBD and PPD are more frequent in ET patients than in general aged population but not related with specific tremor features. ET-RBD patients did not differ significantly from iRBD patients, a group prone to develop PD. These data suggest a link between ET and PD and are in accordance with studies showing an increase incidence of lewy-body pathology and PD in ET populations.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"8 ","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000168/pdfft?md5=b4475837bfa909d9c7ce85474b7d4c19&pid=1-s2.0-S2590142724000168-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management","authors":"Silvia Miano ,&nbsp;Leila Kheirandish-Gozal ,&nbsp;Marco De Pieri","doi":"10.1016/j.sleepx.2024.100126","DOIUrl":"10.1016/j.sleepx.2024.100126","url":null,"abstract":"<div><h3>Introduction</h3><div>Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking concerning their management when coexisting in a same patient.</div></div><div><h3>Methods</h3><div>A narrative review of the literature was realized including PubMed, Scopus and Embase, aimed to regroup studies and case reports evaluating epidemiology, clinical and instrumental features and treatment of patients presenting comorbid NT1 and OSA. Moreover, a snowball search on the pathophysiology underpinnings of the association of the two disorder was realized.</div></div><div><h3>Results</h3><div>For adults, the prevalence of OSA in NT1 ranged from 24.8 % to 51.4 %. No studies were found concerning the treatment of EDS in double-diagnosis patients, but only case reports; these latter and the experience on patients with either NT or OSA suggest that modafinil, methylphenidate, pitolisant and solriamfetol are effective.</div></div><div><h3>Discussion</h3><div>Adults with NT1 showed a higher prevalence of OSA compared to the general population, but the reach of the results reviewed here is limited by the retrospective design of most of the studies and by the inhomogeneous utilization of diagnostic criteria. The association with OSA is likely to be explained by the involvement of orexin in hypercapnic-hypoxic responses: a deficit of orexin may promote obstructive events during sleep. Open questions warrant further investigation, especially orexin's involvement in other sleep disorders associated with EDS, and the more appropriate treatment for the OSA-narcolepsy comorbidity.</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"8 ","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000247/pdfft?md5=6de7d81d052f90264f12650f306bf7ee&pid=1-s2.0-S2590142724000247-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142316174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates","authors":"Asim Roy ,&nbsp;Thomas Stern ,&nbsp;John Harsh ,&nbsp;J. Douglas Hudson ,&nbsp;Akinyemi O. Ajayi ,&nbsp;Bruce C. Corser ,&nbsp;Emmanuel Mignot ,&nbsp;Adrian Santamaria ,&nbsp;Anne Marie Morse ,&nbsp;Brian Abaluck ,&nbsp;Sally Ibrahim ,&nbsp;Paula K. Schweitzer ,&nbsp;Katie Lancaster ,&nbsp;Jordan Dubow ,&nbsp;Jennifer Gudeman","doi":"10.1016/j.sleepx.2024.100122","DOIUrl":"10.1016/j.sleepx.2024.100122","url":null,"abstract":"<div><h3>Objective/Background</h3><p>Preference for extended-release, once-nightly sodium oxybate (ON-SXB, FT218) vs twice-nightly immediate-release (IR) oxybate was assessed in participants switching from IR oxybate to ON-SXB in an open-label/switch study, RESTORE (NCT04451668).</p></div><div><h3>Patients/Methods</h3><p>Participants aged ≥16 years with narcolepsy who completed the phase 3 REST-ON trial, were oxybate-naive, or were on a stable IR oxybate dose (≥1 month) were eligible for RESTORE. For participants who switched from twice-nightly dosing to ON-SXB, initial doses were closest or equivalent to their previous nightly IR oxybate dose. These participants completed a questionnaire at baseline about nocturnal adverse events associated with the middle-of-the-night IR oxybate dose in the preceding 3 months, a preference questionnaire after 3 months of stable-dose ON-SXB, and an end-of-study (EOS) questionnaire.</p></div><div><h3>Results</h3><p>There were 130 switch participants; 92/98 (93.9 %) who completed the preference questionnaire preferred ON-SXB. At baseline, 69.2 % reported missing their second IR oxybate dose at least once; in these cases, 80 % felt worse the next day. Approximately 39 % reported taking a second nightly IR oxybate dose &gt;4 h after the first dose, 51 % of whom felt somewhat to extremely groggy/unsteady the next morning; 120 participants (92 %) reported getting out of bed after their second oxybate dose. Of those, 9 (8 %) reported falls and 5 (4 %) reported injuries. Of the switch participants who completed the EOS questionnaire, 91.2 % felt better able to follow the recommended ON-SXB dosing schedule.</p></div><div><h3>Conclusions</h3><p>The second nightly IR oxybate dose presents significant treatment burdens and adherence concerns. Participants overwhelmingly preferred the once-nightly dosing regimen of ON-SXB.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"8 ","pages":"Article 100122"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259014272400020X/pdfft?md5=774141c3ceeff18615ce020ae63dbf2d&pid=1-s2.0-S259014272400020X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial","authors":"Michael J. Thorpy,&nbsp;Clete A. Kushida,&nbsp;Richard Bogan,&nbsp;Akinyemi O. Ajayi,&nbsp;Bruce C. Corser,&nbsp;Jennifer Gudeman","doi":"10.1016/j.sleepx.2024.100109","DOIUrl":"https://doi.org/10.1016/j.sleepx.2024.100109","url":null,"abstract":"<div><h3>Background</h3><p>Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (<em>P</em> &lt; 0.001 at 6 g, 7.5 g, and 9 g) reductions in cataplexy episodes in participants in the phase 3 REST-ON clinical trial (NCT02720744). This post hoc analysis from REST-ON further characterized changes in cataplexy episodes in participants with narcolepsy type 1 (NT1).</p></div><div><h3>Methods</h3><p>Participants with narcolepsy aged ≥16 years received ON-SXB (1 wk, 4.5 g; 2 wk, 6 g; 5 wk, 7.5 g; 5 wk, 9 g) or placebo. Percentages of participants with NT1 who had ≥25%, ≥50%, ≥75%, and 100% reductions from baseline in mean number of weekly cataplexy episodes were determined. Two-sided <em>P</em> values comparing ON-SXB vs placebo were calculated with Fisher exact test.</p></div><div><h3>Results</h3><p>Participants with NT1 (ON-SXB, n = 73; placebo, n = 72; modified intent-to-treat population) had a baseline mean number of weekly cataplexy episodes of 18.9 (ON-SXB) and 19.8 (placebo). Of participants receiving the highest doses of ON-SXB (7.5 and 9 g), approximately half had a 50% reduction, one-third had a 75% reduction, and one-tenth had a 100% reduction in their cataplexy episodes vs placebo. Significantly greater proportions of participants receiving ON-SXB vs placebo had respective reductions in weekly cataplexy episodes of ≥25% at weeks 1 (4.5 g; <em>P</em> &lt; 0.05), 3 (6 g; <em>P</em> &lt; 0.001), 8 (7.5 g; <em>P</em> &lt; 0.001), and 13 (9 g; <em>P</em> = 0.001).</p></div><div><h3>Conclusions</h3><p>A significantly greater proportion of participants receiving ON-SXB vs placebo experienced reductions in weekly cataplexy episodes at all tested doses. Approximately 10% of participants taking the 2 highest ON-SXB doses had complete elimination of their cataplexy.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"7 ","pages":"Article 100109"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000077/pdfft?md5=3c240260906d5285541adb65be6076fd&pid=1-s2.0-S2590142724000077-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140347962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective evaluation of the impact of multi-channel studies on treatment outcomes in children with sleep disordered breathing","authors":"Michael Yanney ,&nbsp;Nicola Rowbotham ,&nbsp;Christabella Ng ,&nbsp;Muhammad Zulkifli ,&nbsp;Ahmed Shehata ,&nbsp;Alagappan Chidambaram ,&nbsp;Paraskevi Tsirevelou ,&nbsp;Neil Fergie ,&nbsp;Pathik Thakkar ,&nbsp;Emma Crookes ,&nbsp;Roy Dean ,&nbsp;Andrew Prayle","doi":"10.1016/j.sleepx.2024.100111","DOIUrl":"10.1016/j.sleepx.2024.100111","url":null,"abstract":"<div><p>There are significant variations in practice regarding the use of sleep studies in children with symptoms of sleep disordered breathing (SDB) prior to adenotonsillectomy. Current UK guidance recommends the selective use of sleep studies to confirm a diagnosis of obstructive sleep apnoea (OSA) when there is diagnostic uncertainty, in children with comorbidities, or to assess perioperative risk when severe OSA is suspected. We have developed a novel paediatric sleep service over the past decade based on the routine use of multi-channel sleep studies (MCSS) before adenotonsillectomy. We present the results of a prospective evaluation assessing the impact of our service on treatment outcomes.</p><p>We conducted a prospective service evaluation of 49 children with SDB seen between July 2021 and August 2022. We used medical records and a sleep study database to determine treatment outcomes. Otolaryngologists completed a questionnaire before each multi-channel sleep study to help evaluate the impact of sleep study findings on surgical decision making.</p><p>Questionnaire responses before MCSS showed that clinicians thought 66 % of children were ‘likely’, ‘very likely’ or ‘definitely’ would require surgery but only 54 % of children underwent surgery following their sleep study. We estimate that the use of MCSS was associated with a 21 % reduction in children undergoing surgery in this small sample.</p><p>We conclude that our use of MCSS facilitates conservative management, allowing a significant reduction in the number of children with SDB undergoing surgery, but further validation of MCSS against polysomnography is required.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"7 ","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000090/pdfft?md5=2f316020c07fb1bb8d4ff7f7013eeef0&pid=1-s2.0-S2590142724000090-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140767108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep health inequities in vulnerable populations: Beyond sleep deserts","authors":"Zeina Al-Khalil ,&nbsp;Hrayr Attarian ,&nbsp;Galit Levi Dunietz ,&nbsp;Ronald Gavidia Romero ,&nbsp;Kristen Knutson ,&nbsp;Dayna A. Johnson","doi":"10.1016/j.sleepx.2024.100110","DOIUrl":"10.1016/j.sleepx.2024.100110","url":null,"abstract":"<div><p>Despite the importance of sleep to overall health and well-being, there is a high prevalence of undiagnosed sleep disorders and adverse sleep health, particularly among vulnerable populations. Such vulnerable populations include people experiencing homelessness (PEH), refugees, and incarcerated individuals. In this narrative review, we provide an overview of the literature on sleep health and disorders among key and vulnerable populations (e.g., PEH, refugees, and incarcerated individuals). The limited research among these populations indicated a high prevalence of sleep disorders, mainly insomnia, short sleep duration, and fatigue. Substance abuse and PTSD were commonly found among PEH and refugee populations, respectively, which were was related to poor sleep. Similar across the included vulnerable populations, the individuals reside in environments/facilities with inopportune light exposure, noise disruption, inadequate bedding, and forced sleep schedules. Studies also found a high prevalence of psychosocial stress and reports of threats to safety, which were associated with poor sleep health outcomes. Additionally, several studies reported environmental barriers to adherence to sleep disorder treatment. This paper highlighted the conditions in which these vulnerable populations reside, which may inform interventions within these various facilities (homeless shelters, refugee camps, prisons/jails). The improvement of these facilities with a sleep equity focus may in turn improve quality of life and daily functioning.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"7 ","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000089/pdfft?md5=29b43dff8ff4b00ee602a30cd7a417dd&pid=1-s2.0-S2590142724000089-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140401328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Turkish adaptation of the maternal cognition about infant sleep questionnaire","authors":"Hatice Ezgi Baris ,&nbsp;Mahmut Caner Us ,&nbsp;Perran Boran","doi":"10.1016/j.sleepx.2023.100102","DOIUrl":"https://doi.org/10.1016/j.sleepx.2023.100102","url":null,"abstract":"<div><h3>Background</h3><p>Exploring early childhood sleep problems requires a detailed understanding of parental beliefs and cognitions related to infant sleep. There is a need for validated measures to investigate the cognitions of Turkish mothers about infant sleep however no scale measuring parental perceptions related to infant sleep behaviors in Turkish is available. We aimed to culturally adapt the Maternal Cognitions about Infant Sleep Questionnaire (MCISQ) in Turkish.</p></div><div><h3>Methods</h3><p>Subjects were recruited from an internet sample through social media. Internal consistency was evaluated by Cronbach's alpha, and test-retest reliability was determined by Pearson's correlation test and paired <em>t-</em>test. For factorial validity, the principal component factor analysis was performed for the components of MCISQ.</p></div><div><h3>Results</h3><p>A total of 417 mothers, most aged between 25 and 29 years (47.8 %), participated in the study. Infants' age ranged between 6 and 18 months, with a mean of 10.5 ± 3.9 months. Factor analysis revealed four factors after removal of item 11: Anger, doubt, safety, limit setting. Cronbach's alpha was 0.85. A subgroup of 32 mothers completed MCISQ three weeks after the initial administration. Total mean scores showed a significantly strong correlation (p:&lt;0.01, r:0.82). Higher scores were noted in both total and subscale scores in infants with maternally reported sleep problems (p:&lt;0.01).</p></div><div><h3>Conclusion</h3><p>Findings suggest a four-factor solution for MCISQ in Turkish mothers with infants aged 6–18 months. The adapted Turkish version is composed of 19 items with good reliability. Factor structure and items included in the subscales differed from the original study, highlighting the cultural factors related to maternal perceptions about infant sleep.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"7 ","pages":"Article 100102"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142723000423/pdfft?md5=3d72f1f08d142daddd8b76895c704810&pid=1-s2.0-S2590142723000423-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139109128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report on melatonin overdose: Cause and concern","authors":"Richa Tripathi,&nbsp;Hina Bano,&nbsp;Mohd Rashid Alam","doi":"10.1016/j.sleepx.2024.100116","DOIUrl":"10.1016/j.sleepx.2024.100116","url":null,"abstract":"<div><p>Melatonin, the primary hormone secreted by the pineal gland, regulates central and peripheral oscillators and adapts the internal environment to the external one through MT1 and MT2 receptors. The authors present a case of 16-year-old male intentionally overdosed on 900mg of melatonin (180 tablets) and 10 tablets of 0.5mg alprazolam. Admitted to the emergency department, he was extremely drowsy and minimally responsive with a Glasgow coma scale score of 8/15. Vital signs were stable, and no renal or liver dysfunction was noted. Elevated total leucocyte count and positive benzodiazepine urine test were observed. Gastric lavage was performed, and toxicology reports showed blood alprazolam levels at 0.15 mg/litre eight hours post-overdose. The patient regained consciousness 32 hours post-ingestion and was transferred to the psychiatry unit. This case underscores the increasing abuse of melatonin due to its easy availability and lack of regulation. Although melatonin has a low toxicity potential, side effects and interactions with other drugs can be severe. Supportive measures and vital sign control are crucial in overdose treatment.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"7 ","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000144/pdfft?md5=e509b80493c850559efa81b5db5319bd&pid=1-s2.0-S2590142724000144-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141133557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep problems and their predictors in community-dwelling older adults with diabetes in India: Evidence from the Longitudinal Ageing Study in India","authors":"Vansh Maheshwari,&nbsp;Saurav Basu","doi":"10.1016/j.sleepx.2024.100108","DOIUrl":"https://doi.org/10.1016/j.sleepx.2024.100108","url":null,"abstract":"<div><h3>Objectives</h3><p>To ascertain the prevalence and predictors of sleep disorders and poor sleep quality among older adults with Diabetes (DM) in India, and to assess the relationship between sleep quality and DM.</p></div><div><h3>Methods</h3><p>Data was utilized from the nationally representative Longitudinal Ageing Study in India (Wave-1, 2017–18), with a total sample of 66606 older adults (≥45 years) selected for the study. Sleep problems and sleep quality score were assessed using an adaptation based on the Jenkins Sleep Scale. Multivariate linear and logistic regressions were conducted to determine the effect of sociodemographic and clinical factors on sleep quality. Mediation analysis (Karlson-Holm-Breen) was done to assess the direct and indirect effects of independent variables on the sleep quality scores. Further, Propensity score matching (PSM) was done to assess the impact of diabetes on sleep problems.</p></div><div><h3>Results</h3><p>The prevalence of DM was 12.34% (n = 8564, 95% CI: 11.54, 13.20) among whom 24.38% (95% CI: 21.38, 27.65) reported sleep problems. On adjusted analysis, sleep problems were significantly associated with increasing education, higher wealth quintile, lack of physical activity, and multimorbidity. Mediation analysis showed adherence to anti-diabetes medication improved sleep quality (aB = −0.28 (95% CI: −0.54, −0.02)), while comorbidities worsened sleep quality (aB = 0.79 (95% CI: 0.67, 0.92)). Analysis from PSM indicated that DM was associated with a 6.2% higher chance of sleep problems.</p></div><div><h3>Conclusions</h3><p>Poor sleep quality is present in nearly one in four individuals diagnosed with DM in India and linked with certain adverse social determinants. Focused interventions to improve assessment and treatment of sleep problems in resource-limited primary care settings require prioritization.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"7 ","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590142724000065/pdfft?md5=53a93d360faef969736188d530ade49d&pid=1-s2.0-S2590142724000065-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140096310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}